

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Financiere Elitech SAS	06/26/2009
RECEIVING PARTY DATA	
Name:	DXCON, Inc.
Street Address:	6759 Mesa Ridge Road, Suite 100
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	11751537
Patent Number:	6673562
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2028427800
Email:	zpatdcdocketing@cooley.com
Correspondent Name:	Cooley LLP
Address Line 1:	777 6th Street, NW
Address Line 2:	ATTN: Patent Group
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20001
ATTORNEY DOCKET NUMBER:	NEXU-026/02 AND -026/04
NAME OF SUBMITTER:	Mark L. Hayman
Total Attachments: 23 source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page1.tif source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page2.tif	

CH \$80.00 11751537

501179871

PATENT
REEL: 024402 FRAME: 0457

source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page3.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page4.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page5.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page6.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page7.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page8.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page9.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page10.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page11.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page12.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page13.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page14.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page15.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page16.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page17.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page18.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page19.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page20.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page21.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page22.tif
source=NEXU01100USDesignationAndPartialAssignmentFinanciereToDxCon#page23.tif



FINANCIERE ELITECH

12-12 bis rue Jean Jaurès – 92800 Puteaux – France
Tél : +33 (0)1 41 45 07 10 Fax : +33 (0)1 41 45 07 19
Société par actions simplifiée (SAS) au capital de 11 240 480 Euros
Siret : 481 676 062 000 13 – Code APE : 6420Z
R.C.S. NANTERRE B 481 676 062

June 26, 2009

Nanogen, Inc.
10398 Pacific Center Court
San Diego, California 92121

Re: Designation and Partial Assignment of Rights
to Receive Assets under Asset Purchase Agreement

Ladies and Gentlemen:

Reference is made to that certain Asset Purchase Agreement, dated as of May 13, 2009, as amended from time to time (the “APA”), among Financière Elitech SAS (“Elitech”), Nanogen, Inc. (“Nanogen”), Epoch Biosciences, Inc. (“Epoch”) and Nanotronics, Inc. (“Nanotronics” and, collectively with Nanogen and Epoch, the “Sellers” and each a “Seller”). All capitalized terms used in this Designation and Partial Assignment or any attached schedules or exhibits shall have the meanings given in the APA unless otherwise defined herein.

As contemplated under Section 2.1 of the APA, and pursuant to Section 12.10 thereof, Elitech hereby designates DxCon, Inc. (“DxCon”), a Delaware corporation and wholly-owned subsidiary of BCC, to receive from Sellers under the APA all assets related to the Point of Care Business described under Section 2.1 of the APA, including those assets listed on Schedule A attached hereto (collectively, the “Designated Assets”). By signing and acknowledging this Designation and Partial Assignment, DxCon agrees to assume all Assumed Liabilities associated with the Designated Assets in accordance with Section 3.1 of the APA.

Elitech hereby instructs each Seller to transfer the Designated Assets to DxCon at the Closing. To the extent applicable, Elitech also hereby assigns to DxCon its rights to receive certain instruments of transfer from the Sellers under Section 7.1(g)(ii) of the APA as may be necessary to accomplish the transfers contemplated herein. Elitech also hereby assigns its rights under Sections 8.3, 8.8, 8.11, and 8.13 of the APA to DxCon solely with respect to the Designated Assets.

DxCon agrees to provide adequate assurance of future performance for all Assumed Contracts included in the Designated Assets as required by Section 8.6 of the APA.

The undersigned parties agree that DxCon shall be a permitted assignee of Elitech in accordance with Section 12.10 of the APA and that the rights described herein shall inure to the benefit of DxCon without regard to Section 12.15 of the APA.

Except as otherwise expressly set forth above, the rights and obligations of the Sellers and Elitech with respect to the Purchased Assets and the Assumed Liabilities shall remain as set forth in the APA.

This Designation and Partial Assignment may be executed in any number of counterparts, each of which when so executed shall be deemed an original, but all such counterparts shall constitute one and the same instrument.

This Designation and Partial Assignment shall be governed by, and construed in accordance with, the internal laws and decisions of the State of Delaware.


Signature Pages Follow.

Sincerely yours,

Financière Elitech SAS,

By:

Pierre Debiais
President

A handwritten signature in black ink, appearing to be 'Pierre Debiais', is written over a horizontal line. The signature is enclosed within a large, loopy oval shape. A diagonal line is drawn across the signature from the top left to the bottom right.


[Signature page to Designation and Partial Assignment]

ACKNOWLEDGED AND AGREED:

Bay City Capital Fund V, L.P.

By: Bay City Capital Management V LLC,
its General Partner


By: Bay City Capital LLC, its Manager

By: 
William G. Gerber
Investment Partner


**Bay City Capital Fund V Co-Investment Fund,
L.P.**

By: Bay City Capital Management V LLC,
its General Partner

By: Bay City Capital LLC, its Manager


By: 
William G. Gerber
Investment Partner

DxCon, Inc.

By: 
William G. Gerber
President

**ACKNOWLEDGED AS TO DESIGNATION AND
TRANSFER INSTRUCTIONS:**


Nanogen, Inc.

By: 
David Ludvigson
President and COO

Epoch Biosciences, Inc.

By: 
David Ludvigson
President

Nanotronics, Inc.

By: 
David Ludvigson
Director

SCHEDULE A

POINT OF CARE ASSET LIST

Assets being transferred to DxCon:

- All assets directly associated with the Point of Care Business, including, but not limited to, all Intellectual Property, trade names, tangible personal property, inventory and supplies, receivables and prepaids, records, Contracts and licenses and other assets described Section 2.1 of the APA.
- The Vyent, Cardiac STATus and Decision Point product lines
- The NeXus Dx platform
- All equity interests in: Recognomics, Delta Point, and Hx Diagnostics, Inc.
- Trade names: Cardiac STATus, Tox STATus, Vyent, Nexus Dx, Decision Point Diagnostics, and i-Lynx
- Domain names: cardiacstatus.net, statusfirst.com, toxstatus.com

Contracts being assumed by DxCon:

1. License Agreements

1. Second Amended and Restated License Agreement between Nanogen, Inc. and Genzyme Corporation dated May 23, 2007.
2. Development and License Agreement between 2750 Diagnostics, Inc. (now HX Diagnostics, Inc.) and Nanogen, Inc. dated June 30, 2006.
3. Assay Development and License Agreement between HX Diagnostics, Inc. and Nanogen, Inc. dated July 23, 2008. Amendment to Assay Development and License Agreement between HX Diagnostics, Inc. and Nanogen, Inc. dated September 21, 2008. Second Amendment to Assay Development and License Agreement between HX Diagnostics, Inc. and Nanogen, Inc. dated April 1, 2009.
4. Phoenix BioPharm License dated October 1, 2005 and extended October 15, 2008; non-exclusive license for certain antibodies in a stroke therapeutic.
5. License Agreement between International Point of Care, Inc. and Nanogen, Inc. dated October 15, 2008.
6. Offset Agreement between Nanogen, Inc. and International Point of Care, Inc. dated March 19, 2009.

2. In-License

1. License Agreement between Primecare B.V. and Spectral Diagnostics, Inc. dated September 3, 1993.
2. License Agreement between Nanogen, Inc. and LRE GmbH dated July 2, 2008
3. Cross-License Agreement on NT-proBNP between SynX Pharma, Inc. and Roche Diagnostic GmbH dated July 27, 2003.
4. Drug Royalty – License agreement for diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof dated December 18, 1991.

5. License Agreement between Ottawa Heart Institute Research Corporation and Synx Pharma, Inc. dated November 25, 2002.

3. Distribution Agreements

1. Distribution Agreement between Nanogen, Inc. and CV Inti Jaya Lestari dated December 16, 2008.
2. Exclusive Supply and Distribution Agreement Renewal from January 1, 2009 to December 21, 2009 between Nanogen, Inc. and Astra Zeneca GmbH dated January 6, 2009.
3. Distribution Agreement between Nanogen, Inc. and BioCare Systems SA dated March 26, 2009.
4. Distribution Agreement between Nanogen, Inc. and Fuad Al-Fadhli Trading Est dated March 30, 2009.
5. Best Value Distribution Agreement between Cardinal Health and Spectral Diagnostics, Inc. dated January 1, 2003, assumed by Nanogen, Inc.; amended March 1, 2007 between Cardinal Health and Nanogen, Inc.

4. Other

1. Development Agreement between Princeton Biomeditech Corporation and Nanogen, Inc. dated January 13, 2006.
2. Manufacturing and Distribution Agreement between Princeton Biomeditech Corporation and Nanogen, Inc. dated October 27, 2005.
3. Pharmagistics – Distribution and warehousing agreement of product developed under the PBM product development agreement dated 1/13/06; May 30, 2007.
4. Common Stock Purchase Agreement between HX Diagnostics, Inc. and Nanogen, Inc.; dated October 2006; Warrants to Purchase Common Stock dated October 2006 and July 2008; Amendment Number One to the July 2008 Common Stock Purchase Warrant dated January 2009.
5. Consulting Agreement between George Jackowski and Nanogen, Inc.; April 29, 2009.
6. BioRad – Material Transfer Agreement between Nanogen, Inc. and Bio-Rad dated February 11, 2008.
7. Bonfils – Bonfils Blood Center Material Transfer Agreement between Bonfils Blood Center and Nanogen, Inc. dated July 12, 2007.
8. Center Hospitalier Universitaire de Quebec – Materials and Transfer Procurement Agreement between Center Hospitalier Universitaire de Quebec and Nanogen, Inc. dated June 6, 2006.
9. Aventis - Patent Purchase Agreement between Aventis Research & Technologies GmbH & Co. KG and Nanogen, Inc. – June 28, 2002
10. Supply Agreement between Seradyn, Inc. and Nanogen, Inc. dated May 30, 2008.
11. Biosite Settlement Agreement between Spectral Diagnostics, Inc. and Biosite Diagnostics, Inc. dated February 5, 1999 – agreement not to sue; assigned to Nanogen, Inc. in the purchase of Spectral assets.
12. Biosite - Settlement Agreement between SynX Pharma, Inc. and Nanogen, Inc. dated April 22, 2005 – settlement of patent interference

13. Cooperation and Shareholders' Agreement among Aventis Research & Technologies GmbH & Co KG, Nanogen and Nanogen Recognomics GmbH dated June 29, 2001 and Contribution Agreement among Aventis Research & Technologies GmbH & Co KG, Nanogen and Nanogen Recognomics GmbH dated June 27, 2001.

FDA 510(k) clearances being assigned to DxCon:

Product	510(k) #
Cardiac Status CK-MB	K022409
Cardiac Status Tnl	K014105
Cardiac Status Tnl/Myo	K020950
CS CK-MB/Tnl/Myo	K030057
NT-proBNP (whole blood)	K051596
Cardiac Status Controls (CKMB/Myoglobin/Troponin I)	K981474
Cardiac Status Controls (CKMB/Myoglobin)	K972408
Cardiac Status Controls (Troponin I)	K972687
CardioQuant Troponin I Test	K014105

Patents being assigned to DxCon:

a. Europium Immunodiagnostic Panel (13 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	33514-702.201 Methods and Compositions for Analyte Detection	US 11/677,559 US2008-0199851-A1	Filed 2/21/07	Published	Nanogen Wilson Sonsini
2.	33514-702.601PCT Methods and Compositions for Analyte Detection	PCT/US2007/004466	Filed 2/21/07	N/A 30 month done	Nanogen Wilson Sonsini
3.	33514-702.581VN Methods and Compositions for Analyte Detection	VN 1-2009-00243	2/21/07	Pending	Nanogen Wilson Sonsini
4.	33514-702.681AU Methods and Compositions for Analyte Detection	AU 2007217765	2/21/07	Pending	Nanogen Wilson Sonsini
5.	33514-702.701CA Methods and Compositions for Analyte Detection	CA Not yet assigned	2/21/07	Pending	Nanogen Wilson Sonsini
6.	33514-702.741IN Methods and Compositions for Analyte Detection	IN 00270/MUMNP09	2/21/07	Pending	Nanogen Wilson Sonsini
7.	33514-702.821SG Methods and Compositions for Analyte Detection	SG Not yet assigned	2/21/07	Pending	Nanogen Wilson Sonsini
8.	33514-702.911MY Methods and Compositions for Analyte Detection	MY Not yet assigned	2/21/07	Pending	Nanogen Wilson Sonsini
9.	33514-711.601US Methods and Compositions for Analyte Detection	US		Preparing to file	Nanogen Wilson Sonsini
10.	33514-702.602PCT Multianalyte Assay	PCT/US2008/062088	Filed 4/30/08	Pending 30 mo. 10/30/09	Nanogen Wilson Sonsini
11.	33514-702.611EP Multianalyte Assay	EP 7751240.8	Filed 2/21/07	Pending	Nanogen Wilson Sonsini
12.	37610-517P01US Methods for Detecting Nucleic Acids in a Sample	US 61/099,515	Filed 9/23/08	Pending	Nanogen Mintz Levin
13.	Hand-Held Scanner for Reading Point of Care Test Results	US 61/167,485	Filed 4/7/09	Pending	Nanogen Mintz Levin

b. 3n1 Panel (8 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	37610-525001US Diagnostic Kit for Diagnosing and Distinguishing Chest Pain in Early Onset Thereof	US 5,290,678	Filed 5/3/91 Issued 3/1/94	Granted to 5/3/2011	Spectral Mintz Levin

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
2.	37610-525003US Method and Device for Diagnosing and Distinguishing Chest Pain in Early Onset Thereof	US 5,604,105	Filed 4/11/95 Issued 2/18/97	Granted to 5/3/2011	Spectral Mintz Levin
3.	37610-525C01US Diagnostic Kit for Diagnosing and Distinguishing Chest Pain in Early Onset Thereof	US 5,747,274	Filed 9/1/96 Issued 5/5/98	Granted to 5/3/2011	Spectral Mintz Levin
4.	37610-525004US Diagnostic Kit for Diagnosing and Distinguishing Chest Pain in Early Onset Thereof	US 5,710,008	Filed 10/22/96 Issued 1/20/98	Granted to 5/3/2011	Spectral Mintz Levin
5.	37610-525C03US Diagnostic Kit for Diagnosing and Distinguishing Chest Pain in Early Onset Thereof	US 5,744,358	Filed 9/5/96 Issued 4/28/98	Granted to 5/3/2011	Spectral Mintz Levin
6.	37610-525001 Diagnostic Kit for Diagnosing and Distinguishing Chest Pain in Early Onset Thereof	EP 96907627.2	Filed 4/11/96	Granted in Belgium, France, Germany, Italy, Spain, UK	Spectral Mintz Levin
7.	37610-525F01CA Diagnostic Kit for Diagnosing and Distinguishing Chest Pain in Early Onset Thereof	Canada 2027434	Filed 10/12/90 Issued 1/5/99	Granted to 10/12/2010	Spectral Mintz Levin
8.	37610-525001JP Diagnostic Kit for Diagnosing and Distinguishing Chest Pain in Early Onset Thereof	Japan 2628421	Filed 10/9/91 Issued 4/18/97	Granted to 10/9/2011	Spectral Mintz Levin

c. Congestive Heart Failure / NT-pro BNP (30 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	A101 Q87317Conjunctive Analysis of Biological Marker Expression for Predicting Cardiac Mortality	US RE 39,816	Filed 9/4/01 Issued 9/4/07	Granted	Syn X Sughrue Mion

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
2.	101C2US Q104957Conjunctive Analysis of Biological Marker Expression for Predicting Cardiac Mortality	US 11/984,299	Filed 11/15/07	Abandoned	Syn X Sughrue Mion
3.	Q111527 Kit for Determining a Relative Risk of Cardiac Mortality	US 12/354,273	Filed 1/15/09	Pending	SynX Sughrue Mion
4.	F206002 Conjunctive Analysis of Biological Marker Expression for Diagnosing Organ Failure	Canada 2465971 CA2465971	Filed 8/23/02	Published	Syn X Sughrue Mion
5.	F206003 Conjunctive Analysis of Biological Marker Expression for Diagnosing Organ Failure	EP 2759956.2 EP1423705	Filed 8/23/02	Published	Syn X Sughrue Mion
6.	37610-506C01US Diagnostic Methods for Congestive Heart Failure	US-2009-0068676-A1 US 11/786,885	Filed 4/12/07	Published	Syn X Mintz Levin
7.	37610-506001CA Diagnostic Methods for Congestive Heart Failure	Canada 2544838	Filed 11/10/04	Pending	Syn X Mintz Levin
8.	37610-506001EP Diagnostic Methods for Congestive Heart Failure	EP 04797198.1 1692513	Filed 11/10/04	Published	Syn X Mintz Levin
9.	37610-506001JP Diagnostic Methods for Congestive Heart Failure	Japan 2006-538618	Filed 11/10/04	Pending	Syn X Mintz Levin
10.	37610-507C01US Polyclonal-Polyclonal Elisa Assay for Detecting N-Terminus proBNP	US 11/440,809 US2006-0211070	Filed 5/25/06	Published	Syn X Mintz Levin
11.	37610-507001CA Polyclonal-Polyclonal Elisa Assay for Detecting N-Terminus proBNP	Canada 2503709	Filed 11/17/03	Pending	Syn X Mintz Levin
12.	37610-507001EP Polyclonal-Polyclonal Elisa Assay for Detecting N-Terminus proBNP	EP 03811320.5 1563310	Filed 11/17/03	Published	Syn X Mintz Levin
13.	37610-507001JP Polyclonal-Polyclonal Elisa Assay for Detecting N-Terminus proBNP	Japan 2004-552311 2006-506623	Filed 11/17/03	Published	Syn X Mintz Levin
14.	37610-501C03US Polyclonal-Monoclonal Elisa Assay for Detecting N-Terminus pro-BNP	US 12/421,409	Filed 4/9/08	Pending	Syn X Mintz Levin

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
15.	37610-501C02US Polyclonal-Monoclonal ELISA Assay for Detecting N-Terminus proBNP	US 11/375,432 US 7,527,939	Filed 3/31/06 Issued 5/5/09	Granted	Syn X Mintz Levin
16.	37610-501001CA Polyclonal-Monoclonal ELISA Assay for Detecting N-Terminus proBNP	Canada 2511680	Filed 11/17/03	Pending	Syn X Mintz Levin
17.	37610-501001EP Polyclonal-Monoclonal ELISA Assay for Detecting N-Terminus proBNP	EP 03811319.7 1562990	Filed 11/17/03	Published	Syn X Mintz Levin
18.	37610-501001JP Polyclonal-Monoclonal ELISA Assay for Detecting N-Terminus proBNP	Japan 2004-570255 2006-521535	Filed 11/17/03	Published	Syn X Mintz Levin
19.	37610-501C02US Polyclonal-Monoclonal ELISA Assay for Detecting N-Terminus proBNP	US 11/375,432 US 2006-0154321	Filed 3/13/06	Published	Syn X Mintz Levin
20.	37610-502C01US Monoclonal Antibodies Against N-Terminus proBNP	US 6,960,472	Filed 2/4/03 Issued 11/1/05	Granted to 11/18/2022	Syn X Exclusive License from Ottawa Heart Institute Mintz Levin
21.	37610-502001AU Monoclonal Antibodies Against N-Terminus proBNP	AU2003283162 3283162AA	Filed 11/17/03	Published	Syn X Exclusive License from Ottawa Heart Institute Mintz Levin
22.	37610-502001CA Monoclonal Antibodies Against N-Terminus proBNP	CA 2,503,708 2503708AA	Filed 11/17/03	Published	Syn X Exclusive License from Ottawa Heart Institute Mintz Levin
23.	37610-502001EP Monoclonal Antibodies Against N-Terminus proBNP	EP 03775024.7 1562989A1	Filed 11/17/03	Pending	Syn X Exclusive License from Ottawa Heart Institute Mintz Levin

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
24.	37610-502001NZ Monoclonal Antibodies Against N-Terminus proBNP	NZ 539874	Filed 11/17/03 Issued 2/8/07	Granted to 11/17/2023	Syn X Mintz Levin
25.	37610-502001JP Monoclonal Antibodies Against N-Terminus proBNP	Japan 2004-570256 2006-517396	Filed 11/17/03	Published	Syn X Exclusive License from Ottawa Heart Institute Mintz Levin
26.	37610-509F01US Calibrator for NT-pro-BNP Immunoassay	US 10/359,028 US 2004-0152128	Filed 2/4/03	Published	Syn X Mintz Levin
27.	2132.044US Biopolymer Marker Indicative of Disease State Having a Molecular Weight of 1793 Daltons	US 6,998,243	Filed 4/30/01 Issued 2/14/06	Abandoned Good to 2/14/2026	Syn X In back file room
28.	BNP as an Indicator of Cardiac Allograft Rejection	US 6,117,644	Filed 6/4/98 Issued 9/12/00	Granted	Syn X Exclusive License from Ottawa Heart Institute Licensor prosecuting/ managing
29.	Predicting and Detecting Cardiac Allograft Rejection	Canada 2233724	Filed 03/31/98	Granted	Syn X Exclusive License from Ottawa Heart Institute Licensor prosecuting/ managing
30.	Predicting, Detecting and Monitoring Treatment of Cardiomyopathies and Myocarditis	US 2004-0132013A1	Filed 11/13/03	Published	Syn X Excl. License from Ottawa Heart Institute Licensor prosecuting (F&R)

d. Other Cardiac (9 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	37610-503F01US Method of Confirming the Presence of Myocardial Infarction	US 10/325,162 US 2004-0121306	Filed 12/20/02	Published	Syn X Mintz Levin
2.	37610-521F01US Monoclonal Antibody to Human Cardiac Myoglobin	US 5,573,957	Filed 9/28/94 Issued 11/12/96	Granted to 9/28/2014	Syn X Mintz Levin
3.	37610-521001CA Monoclonal Antibody to Human Cardiac Myoglobin	Canada 2,201,153	Filed 3/26/97 Issued 11/21/06	Granted to 9/28,2015	Syn X Mintz Levin
4.	37610-521001JP Monoclonal Antibody to Human Cardiac Myoglobin	Japan 3108103	Filed 3/28/97 Issued 9/8/00	Granted to 9/28/2015	Syn X Mintz Levin
5.	37610-524003US Differential Immunoassay	US 6,673,562	Filed 8/23/01 Issued 1/6/04	Granted to 8/23/2021	Syn X Mintz Levin
6.	37610-524D02US Differential Immunoassay	US 11/751,537 2008-0311591	Filed 5/21/07	Published	Spectral Mintz Levin
7.	37610-524001CA Differential Immunoassay	Canada 2420327	Filed 2/24/03	Pending	Spectral Mintz Levin
8.	37610-524D02EP Differential Immunoassay	EP 8075097.9 1947459	Filed 8/24/01	Published	Spectral Mintz Levin
9.	37610-528F01US Single-Chain Polypeptides Comprising Creatine Kinase M and Creatine Kinase B	US 5,981,249	Filed 2/5/98 Issued 9/9/99	Granted to 2/5/2018	Spectral Mintz Levin

e. Stroke (10 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	37610-504F01US Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	US 6,235,489	Filed 2/22/00 Issued 5/22/01	Granted to 2/22/2020	Syn X Mintz Levin

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
2.	37610-504D01US Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	US 6,780,606	Filed 7/21/00 Issued 8/24/04	Granted	Syn X Mintz Levin
3.	8002C Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	US 10/924,283 US-2005-0136496A1	Filed 8/23/04	Published	Syn X KL/Gates
4.	8002EP Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	EP 00906097.1 EPO 1155325	Filed 2/22/00 Issued 11/ 24/04	Granted, France, Germany, UK, Italy, Spain, and Switzerland to 2/22/2020	Syn X KL/Gates
5.	8002BEP Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	EPO 04027808.7	Filed 11/23/04	Pending Austria, Belgium, Cyprus Denmark Finland, France, Germany, Greece, UK, Ireland, Italy, Luxembourg, Monaco, Macedonia, Portugal, Spain, Sweden, Switzerland	Syn X KL/Gates
6.	8002AU Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	Australia 765923	Filed 2/22/00 Issued 1/15/04	Abandoned NC Granted	Syn X KL/Gates
7.	8002CA Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	Canada 2,263,063	Filed 2/26/99 Issued 8/10/04	Granted to 2/26/2019	Syn X KL/Gates
8.	8002JP Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	Japan 2000-602637	Filed 2/22/00	Pending	Syn X KL/Gates

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
9.	8002MX Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	Mexico 228442	Filed 2/22/00 Issued 6/13/05	Granted to 2/22/2020	Syn X KL/Gates
10.	8002NZ Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein	NZ 513005	Filed 2/22/00 Issued 7/25/03	Granted to 2/22/2020	Syn X KL/Gates

f. Traumatic Brain Injury (1 item)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	37610-505C01US Methods for Predicting Outcome in Traumatic Brain Injury	US 11/737,561 2007-0184507	Filed 4/19/07	Published	Syn X Mintz Levin

g. Lateral Flow (13 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	37610-522001EP Analytical Test Device and Method for use in Medical Diagnosis	EP99940165.6 EP 1102989	Filed 8/6/99 Issued 4/16/03	Granted- Austria, Belgium, Switzerland, Germany, France, UK, Ireland, Italy to 8/6/2019	Spectral Mintz Levin
2.	37610-522001CA Analytical Test Device and Method for Use in Medical Diagnosis	CA 2,339,599	Filed 2/2/01	Pending	Spectral Mintz Levin
3.	37610-522001JP Analytical Test Device and Method for Use in Medical Diagnosis	JP2000-564049	Filed 8/6/99	Pending	Spectral Mintz Levin
4.	37610-522F01US Analytical Test Device and Method for Use in Medical Diagnosis	US 6,171,870	Filed 8/6/98 Issued 1/9/01	Granted to 8/6/2018	Spectral Mintz Levin

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
5.	37610-522C01US Analytical Test Device and Method for Use in Medical Diagnosis	US 6,673,628	Filed 2/6/01 Issued 1/6/04	Granted to 8/6/2019	Spectral Mintz Levin
6.	37610-522002US Analytical Test Device and Method for Use in Medical Diagnoses	US 6,410,341	Filed 7/14/99 Issued 6/25/02	Granted to 8/6/2018	Spectral Mintz Levin
7.	37610-522003US Analytical Test Device and Method for use in Medical Diagnoses	US 6,214,629	Filed 7/14/99 Issued 4/10/01	Granted to 8/6/2018	Spectral Mintz Levin
8.	37610-523001CA Diagnostic Device	CA 2,501,124	Filed 10/24/03	Pending	Spectral Mintz Levin
9.	37610-523001US Diagnostic Device for Analyte Detection	US 7,256,053	Filed 10/24/02 Issued 8/14/07	Granted to 10/24/2022	Spectral Mintz Levin
10.	37610-523N01US Diagnostic Device	US 10/531,912	Filed 10/24/03	Published	Spectral Mintz Levin
11.	37610-526C01US Lateral Flow Filter Devices for Separation of Body Fluids From Particulate Materials	US 5,916,521	Filed 6/19/97 Issued 6/29/99	Granted to 1/4/2015	Spectral Mintz Levin
12.	37610-527001EP Immunoassay with Whole Blood	EP97907232.9 EP 00888547B1	Filed 3/13/97 Issued 3/12/03	Granted- Austria, Belgium, France, Germany, Ireland, Switzerland, UK until 3/13/2017	Spectral Mintz Levin
13.	37610-531F01US Immunoassay Test Kit with Funnel	US D405,539	Filed 12/18/95 Granted 2/9/99	Granted to 2/9/2013	Spectral Mintz Levin

h. Blood Filter Membrane (3 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	37610-530001EP A Process and Device for the Separation of a Body Fluid Particulate Materials in Said Fluid and Testing Kit for Said Separation and Analysis of the Body Fluid	EP 0336483	Filed 3/23/89 Issued 6/29/94	Granted- Belgium, France, Germany, Greece, Italy, UK To 3/23/2009	Spectral Mintz Levin
2.	37610-530001JP Particle Separation Method and Apparatus	JP 2729503	Filed 3/29/89 Issued 12/19/97	Granted to 3/23/2009	Spectral Mintz Levin
3.	37610-530001US Process and Device for the Separation of a Body Fluid Form Particulate Materials	US 5,240,862	Filed 3/23/89 Issued 8/31/93	Granted to 8/31/2010	Spectral Mintz Levin

i. pRNA / Nexus DX platform / Recognomics (49 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	8005 Supramolecular Pairing System, its Preparation and Use	US 6,689,884	Filed 8/3/00 Issued 2/10/04	Granted to 9/21/2018	Nanogen Recognomics KL/Gates
2.	8005B Supramolecular Pairing System, its Preparation and Use	US 7,439,345	Filed 12/23/03 Issued 10/21/08	Granted	Nanogen Recognomics KL/Gates
3.	197at12au Cyclohexyl and Heterocyclyl Nucleoside Derivatives, Method for Producing These Derivatives, and the Use of the Derivatives and their Oligomere or Conjugates in Pairing and/or Testing Systems	AU 752521	Filed 9/21/98 Issued 9/19/02	Granted	Nanogen Recognomics Dr. Ackermann

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
4.	197at12jp Cyclohexyl and Heterocyclyl Nucleoside Derivatives, Method for Producing These Derivatives, and the Use of the Derivatives and their Oligomere or Conjugates in Pairing and/or Testing Systems	JP 2000-512817	Filed 9/21/98	Pending	Nanogen Recognomics Dr. Ackermann
5.	2000-017US Method for Producing a Pyranosyl Nucleic Acid Conjugate	US 6,613,894	Filed 9/21/98 Issued 9/2/03	Granted	Nanogen Recognomics O'Melveny
6.	197at13bep Method for Producing a Pyranosyl Nucleic Acid Conjugate (counterpart to 6,613,894)	EPO 10194223	Filed 9/21/98 Issued 2/26/03	Granted – Austria, Switzerland, Germany, France, UK, Italy, Netherlands	Nanogen Recognomics Dr. Ackermann
7.	197at13bjp Method for Producing a Pyranosyl Nucleic Acid Conjugate (counterpart to 6,613,894)	JP 2000-512845	Filed 9/21/98	Pending	Nanogen Recognomics Dr. Ackermann
8.	197at13bau Method for Producing a Pyranosyl Nucleic Acid Conjugate (counterpart to 6,613,894)	Australia 751058	Filed 9/21/98 Issued 8/2/02	Granted	Nanogen Recognomics Dr. Ackermann
9.	2000-024US Use of a Pentopyranosyl Nucleoside for Producing an Electronic Component and Conjugate of said Pentopyranosyle Nucleoside	US 6,506,896	Filed 9/21/98 Issued 1/13/03	Granted	Nanogen Recognomics O'Melveny
10.	197at13cep Use of a Pentopyranosyl Nucleoside Containing a Conjugate for Producing an Array (counterpart to US 6,506,896)	EPO 1017704	Filed 9/21/98 Issued 2/25/04	Granted – Austria, Switzerland, Germany, France, UK, Italy, Netherlands	Nanogen Recognomics Dr. Ackermann
11.	197at13cjp Use of a Pentopyranosyl Nucleoside Containing a Conjugate for Producing an Array (counterpart to US 6,506,896)	Japan 2000-512846	Filed 9/21/98	Pending	Nanogen Recognomics Dr. Ackermann

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
12.	2000-024C1US Pentapyranosyl Nucleic Acid Arrays, and Uses Thereof (continuation of 6,506,896)	US 7,153,955	Filed 5/16/02 Issued 12/26/06	Granted see 2000-024	Nanogen Recognomics O'Melveny
13.	2000-024C2US Pentapyranosyl Nucleic Acid Arrays, and Uses Thereof (continuation of 7,153,555)	US 7,501,506	Filed 8/3/06 Issued 3/10/09	Granted	Nanogen Recognomics O'Melveny
14.	2000-019US Pyranosyl Nucleic Acid Conjugates	US 6,608,186	Filed 9/21/98 Issued 8/19/03	Abandoned NC Granted	Nanogen Recognomics O'Melveny
15.	2000-024D1US Process for Preparing a Pentopyranosyl Nucleic Acid Conjugate	US 12/389,789	Filed 2/20/09	Pending	Nanogen Recognomics O'Melveny
16.	197at11au Addressable Modular Recognition System, Production Mode and Use	AU 757912	Filed 9/21/98 Issued 3/13/03	Granted	Nanogen Recognomics Dr. Ackermann
17.	197at11ep Addressable Modular Recognition System, Production Mode and Use	EP 1018007	Filed 9/21/98 Issued 7/26/06	Granted – France, UK, Italy	Nanogen Recognomics Dr. Ackermann
18.	197at11jp Addressable Modular Recognition System, Production Mode and Use	JP 2000-513140	Filed 9/21/98	Pending	Nanogen Recognomics Dr. Ackermann
19.	197at13ep Pentopyranosyl Nucleoside, and Production and Use of the Same (counterpart to 6,608,186)	EP 1017703	Filed 9/21/98 Issued 4/28/04	Granted – Austria, Switzerland, Germany, France, UK, Italy, Netherlands	Nanogen Recognomics Dr. Ackermann
20.	197at13au Pentopyranosyl Nucleoside, and Production and Use of the Same (counterpart to 6,608,186)	Australia 757983	Filed 9/21/98 Issued 7/3/03	Granted	Nanogen Recognomics Dr. Ackermann

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
21.	197at13ca Pentopyranosyl Nucleoside, and Production and Use of the Same (counterpart to 6,608,186)	Canada	Filed 9/21/98	Allowed	Nanogen Recognomics Dr. Ackermann
22.	197at13jp Pentopyranosyl Nucleoside, and Production and Use of the Same (counterpart to 6,608,186)	Japan 2000-512844	Filed 9/21/98	Pending	Nanogen Recognomics Dr. Ackermann
23.	197at13kr Pentopyranosyl Nucleoside, and Production and Use of the Same (counterpart to 6,608,186)	KR 571299	Filed 9/21/98 Issued 4/10/06	Granted	Nanogen Recognomics Dr. Ackermann
24.	2000-025US Linker Nucleoside, and Production and Use of the Same	US 6,699,978	Filed 9/21/98 Issued 3/2/04	Abandoned NCGranted	Nanogen Recognomics O'Melveny
25.	197at14ep Linker Nucleoside, and Production and Use of the Same (counterpart to 6,699,978)	EP 1034180	Filed 9/21/98 Issued 3/29/06	Granted – Germany, France, UK, Italy	Nanogen Recognomics Dr. Ackermann
26.	197at14au Linker Nucleoside, and Production and Use of the Same (counterpart to 6,699,978)	Australia 758101	Filed 9/21/98 Issued 3/13/03	Granted	Nanogen Recognomics Dr. Ackermann
27.	197at14jp Linker Nucleoside, and Production and Use of the Same (counterpart to 6,699,978)	Japan 2000-512847	Filed 9/21/98	Pending	Nanogen Recognomics Dr. Ackermann
28.	2000-020US Method for the Production of Pentopyranosyl Nucleosides	US 6,545,134	Filed 4/7/99 Issued 4/8/03	Granted	Nanogen Recognomics O'Melveny
29.	2000-014US Enzymatic Modification of a Nucleic Acid-Synthetic Binding Unit Conjugate	US 6,893,822	Filed 7/19/01 Issued 5/17/05	Granted	Nanogen Recognomics O'Melveny
30.	201at18ep Sorting and Immobilization System for Nucleic Acids using Synthetic Binding Systems (CIP counterpart of 6,893,822)	EP 02724166.0	Filed 8/14/02	Pending	Nanogen Recognomics Dr. Ackermann

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
31.	201at18jp Sorting and Immobilization System for Nucleic Acids using Synthetic Binding Systems (CIP counterpart of 6,893,822)	Japan 2003-514953	Filed 8/14/02	Pending	Nanogen Recognomics Dr. Ackermann
32.	8012US 3'-Desxypentopyranosyl Nucleic Acid, Its Product and its Use	US 6,696,555	Filed 4/19/01 Issued 2/24/04	Granted to 8/18/2019	Nanogen Recognomics KL/Gates
33.	8012CUS 3'-Deoxypentopyranosyl Nucleic Acid, Its Product and its Use (continuation of 6,696,555)	US 11/445,037 US 2006-0217546-A1	Filed 5/31/06	Published	Nanogen Recognomics KL/Gates
34.	198at27ep 3'-Desoxypentopyranosyl Nucleic Acid, Its Product and its Use (counterpart to 6,696,555)	EP99945989.4	Filed 8/18/99	Pending	Nanogen Recognomics Dr. Ackermann
35.	198at27de 3'-Desoxypentopyranosyl Nucleic Acid, Its Product and its Use (continuation of 6,696,555)	Germany DE19837387.2	Filed 8/18/98	Pending	Nanogen Recognomics Dr. Ackermann
36.	187at27au 3'-Desoxypentopyranosyl Nucleic Acid, Its Product and its Use (continuation of 6,696,555)	Australia 757446	Filed 8/18/99 Issued 6/5/03	Granted	Nanogen Recognomics Dr. Ackermann
37.	198at27ca 3'-Desoxypentopyranosyl Nucleic Acid, Its Product and its Use (continuation of 6,696,555)	Canada 2340931	Filed 8/18/99	Pending	Nanogen Recognomics Dr. Ackermann
38.	198at27jp -Desoxypentopyranosyl Nucleic Acid, Its Product and its Use (continuation of 6,696,555)	JP 2000-566283	Filed 8/18/98	Pending	Nanogen Recognomics Dr. Ackermann
39.	198at34au Test System for Detecting Different Analytes	Australia 773046	Filed 12/22/99 Issued 8/26/04	Abandoned NC Granted	Nanogen Recognomics Dr. Ackermann
40.	198at34ca Test System for Detecting Different Analytes	Canada 2353920	Filed 12/22/99	Abandoned NC Pending	Nanogen Recognomics Dr. Ackermann

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
41.	198at34de Test System for Detecting Different Analytes	Germany 19859912	Filed 12/23/98 Issued 6/21/01	Abandoned NC Granted	Nanogen Recognomics Dr. Ackermann
42.	198at34jp Test System for Detecting Different Analytes	Japan 2000-5911429	Filed 12/22/99	Abandoned NC Pending	Nanogen Recognomics Dr. Ackermann
43.	2000-011US Biomolecules Having Multiple Attachment Moieties for Binding a Substrate Surface	US 7,186,813	Filed 7/10/02 Issued 3/6/07	Granted	Nanogen Recognomics O'Melveny
44.	2000-011D1US Biomolecules Having Multiple Attachment Moieties for Binding a Substrate Surface	US 11/655,009	Filed 1/18/07	Pending	Nanogen Recognomics O'Melveny
45.	200at02ep Biolomecules Having Multiple Attachment Moieties for Binding a Substrate Surface	EP 1257695	Filed 8/11/00 Issued 3/7/07	Granted – Switzerland, Germany, France, UK, Ireland, Italy	Nanogen Recognomics Dr. Ackermann
46.	2000-011JP Biomolecules Having Multiple Attachment Moieties for Binding a Substrate Surface	JP 2001-551260	Filed 7/11/02	Pending	Nanogen Recognomics O'Melveny
47.	2000-032US New Hydrazide Building Blocks and Modified Biomolecules for Immobilization and Conjugation	US 7,129,229	Filed 2/7/03 Issued 10/31/06	Granted	Nanogen Recognomics O'Melveny
48.	200at02bep New Hydrazide Building Blocks and Modified Biomolecules for Immobilization and Conjugation	EP 1309730	Filed 8/10/01 Issued 11/26/08	Granted – Germany, France, UK, Italy	Nanogen Recognomics Dr. Ackermann
49.	200at02bjp New Hydrazide Building Blocks and Modified Biomolecules for Immobilization and Conjugation	JP 2002-519683	Filed 8/10/01	Pending	Nanogen Recognomics Dr. Ackermann

j. Avian Flu Antibodies (9 items)

	Title	App/Patent No.	Filing/ Issuance Dates	Status	Source
1.	33514-709.601PCT Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	PCT/US2007/002491	01/26/07	Published 30 mo. Done	Nanogen Wilson Sonsini
2.	33514-709.611EP Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	7717131.2 1977015	01/26/07	Published	Nanogen Wilson Sonsini
3.	33514-709.701CA Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	20070036346 2637837	01/26/07	Published	Nanogen Wilson Sonsini
4.	33514-709.711CN Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	610002312.1	01/26/07	Pending	Nanogen Wilson Sonsini
5.	33514-709.712CN Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	7080003646 11379397	01/26/07	Published	Nanogen Wilson Sonsini
6.	33514-709.761JP Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	2008552496	01/26/07	Pending	Nanogen Wilson Sonsini
7.	33514-709.771KR Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	2008107020780 8090532	01/26/07	Published	Nanogen Wilson Sonsini
8.	33514-709.821SG Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	Not yet assigned	01/26/07	Pending	Nanogen Wilson Sonsini
9.	33514-709.831US Monoclonal Antibodies Binding to Avian Influenza Virus Subtype H5 Haemagglutinin	12/162,343 2009-0068637	07/25/08	Published	Nanogen Wilson Sonsini